How to Get Jatenzo in Massachusetts

Massachusetts Telehealth Rules for Jatenzo Prescribing

Massachusetts permits telehealth prescribing of Schedule III controlled substances without a mandatory in-person visit. This is the fastest path to a Jatenzo prescription for most men in the state.

The Massachusetts Board of Registration in Medicine updated its telehealth guidance following the Ryan Haight Act's pandemic-era flexibilities, which the DEA extended through 2025 and proposed to formalize via special registration. Providers must hold an active Massachusetts medical license, maintain a DEA registration with a Massachusetts address, and document a proper patient-provider relationship during the synchronous video visit. Audio-only encounters do not satisfy the requirement for initial controlled substance prescriptions in Massachusetts.

Telehealth platforms that prescribe testosterone replacement therapy (TRT) in Massachusetts typically follow this workflow: the patient submits intake forms and prior lab work, completes a video consultation with a licensed provider, and receives a prescription sent electronically to a pharmacy licensed to dispense in the state. The entire process from sign-up to e-prescription can take as few as 48 hours if labs are already on file. Patients without recent bloodwork should expect an additional 3 to 5 business days for lab orders to be completed and reviewed 1.

Lab Requirements Before Getting Jatenzo in Massachusetts

Two confirmed morning total testosterone levels below 300 ng/dL form the diagnostic foundation. No Massachusetts prescriber should initiate Jatenzo without this documentation.

The Endocrine Society's 2018 clinical practice guideline specifies that hypogonadism diagnosis requires at least two early-morning (before 10 AM) serum total testosterone measurements using a reliable assay, combined with signs and symptoms of androgen deficiency 2. Massachusetts providers routinely order the following baseline panel before prescribing:

• Total testosterone (two separate draws, fasting, before 10 AM)
• Free testosterone or SHBG for calculated free T
• Complete blood count (CBC) with hematocrit
• Comprehensive metabolic panel
• Lipid panel (total cholesterol, LDL, HDL, triglycerides)
• PSA (for men over 40, or over 35 with family history)
• LH and FSH (to differentiate primary from secondary hypogonadism)

Hematocrit deserves special attention with Jatenzo. In the key phase 3 trial by Swerdloff et al. (2020), 3.3% of men on oral testosterone undecanoate developed hematocrit above 54%, compared to the higher rates historically seen with injectable formulations 1. Massachusetts prescribers should recheck CBC at 3 months, 6 months, and annually thereafter per the FDA-approved labeling.

Prior Authorization for MassHealth (Massachusetts Medicaid)

MassHealth covers Jatenzo for male hypogonadism, but requires prior authorization before the pharmacy can dispense.

The PA process in Massachusetts involves the prescriber submitting clinical documentation proving the patient meets diagnostic criteria. Required elements include: two documented low morning testosterone values, clinical symptoms of hypogonadism, and confirmation that the patient does not have contraindications (breast or prostate cancer, hematocrit above 54%, uncontrolled heart failure, or desire for fertility preservation without concomitant therapy).

PA turnaround from MassHealth typically runs 48 to 72 hours for standard requests. Urgent requests can be processed within 24 hours if the prescriber documents medical necessity for expedited review. Denials can be appealed within 30 days, and the prescriber should include the Swerdloff et al. trial data showing that oral TU achieved eugonadal testosterone levels (average Cavg of 489 ng/dL at the 237 mg dose) without the cardiovascular signal concerns that prompted the FDA class-wide labeling update 1.

For commercial insurance in Massachusetts, coverage varies by plan. Most Blue Cross Blue Shield of Massachusetts and Harvard Pilgrim plans cover Jatenzo with step therapy (requiring documentation that topical testosterone was tried and failed, caused skin transfer concerns, or was otherwise inappropriate). Tufts Health Plan requires similar documentation plus a formulary exception form if Jatenzo is not on the preferred tier.

Finding a Jatenzo Prescriber in Massachusetts

Three provider types can prescribe Jatenzo in Massachusetts: physicians (MD/DO), nurse practitioners, and physician assistants.

Massachusetts nurse practitioners gained full practice authority in January 2021 under state law, meaning NPs with prescriptive authority can independently prescribe Schedule III medications including Jatenzo without physician oversight. Physician assistants must practice under a supervising physician's delegation agreement but can prescribe CIII substances within that scope. This means patients in underserved areas of Western Massachusetts or Cape Cod have multiple prescriber options beyond endocrinologists.

Specialty matters less than clinical competence with TRT. Endocrinologists, urologists, and men's health-focused primary care providers all prescribe Jatenzo in Massachusetts. Telehealth platforms staffed by board-certified urologists or endocrinologists offer the most streamlined experience because their workflows are built specifically around hormone therapy protocols: lab ordering, dosing adjustments, and ongoing monitoring are integrated into a single platform rather than spread across multiple offices.

The Massachusetts Medical Society physician finder and the Board of Registration in Medicine's license verification tool allow patients to confirm a provider's active license and disciplinary history before scheduling. For telehealth, verify that the platform's providers hold Massachusetts-specific licensure rather than relying solely on interstate compacts (Massachusetts has not joined the Interstate Medical Licensure Compact as of 2026).

Pharmacy Options: Retail, Specialty, and 503A Compounding

Massachusetts patients have three pharmacy pathways for oral testosterone undecanoate: retail chains, specialty pharmacies, and 503A compounding pharmacies.

Brand Jatenzo at retail pharmacies. CVS, Walgreens, and independent Massachusetts pharmacies can order and dispense Jatenzo. The average cash price without insurance runs between $580 and $750 for a 30-day supply, though manufacturer copay cards may reduce out-of-pocket costs significantly for commercially insured patients. GoodRx and similar discount platforms sometimes show prices below $500 at select Massachusetts locations.

Specialty pharmacy dispensing. Some insurance plans require Jatenzo to be filled through a designated specialty pharmacy. These pharmacies (Accredo, CVS Specialty, OptumRx Specialty) ship directly to the patient's Massachusetts address, typically with cold-chain packaging if required. Turnaround averages 5 to 7 business days after PA approval.

503A compounding pharmacies. Massachusetts licenses 503A compounding pharmacies that can prepare oral testosterone undecanoate capsules as patient-specific prescriptions. These pharmacies must comply with Massachusetts Board of Pharmacy regulations (247 CMR 6.00) and USP 795 standards for non-sterile compounding. Compounded oral TU capsules may cost 40% to 60% less than brand Jatenzo, though bioavailability has not been verified against the Jatenzo-specific SEDDS (self-emulsifying drug delivery system) formulation in controlled trials 3.

A critical distinction: Jatenzo's proprietary lipid-based formulation achieves its pharmacokinetic profile specifically because of the SEDDS technology, which promotes lymphatic absorption and bypasses first-pass hepatic metabolism. Generic or compounded oral testosterone undecanoate may not replicate this absorption pathway, and the FDA label states that Jatenzo is not interchangeable with other oral testosterone products.

Dosing and Clinical Monitoring After Starting Jatenzo

The starting dose is 237 mg taken twice daily with food. Dose adjustments happen at the 4-to-6-week mark based on serum testosterone levels.

The Swerdloff et al. phase 3 study established the titration protocol: patients begin at 237 mg BID, and the dose is adjusted upward to 316 mg or 396 mg, or downward to 158 mg, based on a steady-state testosterone level drawn 3 to 5 hours after the morning dose 1. In that trial (N=166), 87% of men achieved average testosterone concentrations within the eugonadal range (300 to 1 to 100 ng/dL) by week 13.

Food is non-negotiable. Taking Jatenzo without a meal containing at least 15 to 20 grams of fat reduces absorption by approximately 40%, potentially dropping testosterone levels below therapeutic range. Massachusetts providers should counsel patients explicitly on this point at every visit.

Monitoring cadence for Massachusetts patients on Jatenzo should follow Endocrine Society guidelines:

• Testosterone level: 4 to 6 weeks after initiation or dose change (drawn 3 to 5 hours post-morning dose)
• Hematocrit: 3 months, 6 months, then annually
• PSA: baseline, 3 to 6 months, then per USPSTF screening recommendations
• Lipids: 6 to 12 months (oral TU can raise LDL modestly)
• Blood pressure: every visit (the FDA label carries a boxed warning for blood pressure increases) 3
• Liver function: not routinely required (Jatenzo's lymphatic absorption largely bypasses hepatotoxicity risk seen with older 17-alpha-alkylated oral androgens)

Blood Pressure Monitoring: The Boxed Warning

Jatenzo carries an FDA boxed warning for dose-dependent increases in systolic blood pressure. Massachusetts prescribers must document baseline BP and monitor it at every follow-up.

In the open-label safety extension of the key trial, mean increases of 3 to 5 mmHg systolic were observed at the 237 mg dose, with larger increases at 396 mg 1. The FDA mandated a REMS-like monitoring requirement: prescribers must assess blood pressure before starting therapy, re-evaluate at the first follow-up, and at each subsequent visit. Patients with pre-existing hypertension (systolic above 140 mmHg or diastolic above 90 mmHg) should have their antihypertensive regimen optimized before or concurrent with Jatenzo initiation.

For Massachusetts telehealth patients who cannot attend in-person BP checks, validated home blood pressure monitors (devices with AAMI/ISO certification) provide an acceptable alternative. The prescriber should document the device model, instruct the patient on proper measurement technique (seated, 5 minutes rest, supported arm, two readings averaged), and review a 7-day log at each telehealth follow-up 4.

Timeline: From Consultation to First Dose in Massachusetts

Most Massachusetts patients can go from initial inquiry to first capsule in 7 to 14 days. Here is a realistic breakdown.

Days 1 to 2: Complete online intake, upload existing labs or receive lab orders. If using a telehealth platform with a Quest or Labcorp integration, Massachusetts has over 80 draw sites across the state.

Days 3 to 5: Lab results return. For patients with labs already on file (drawn within 90 days), this step is skipped.

Days 5 to 7: Video consultation with licensed Massachusetts provider. Diagnosis confirmed. Prescription submitted electronically.

Days 7 to 10: Prior authorization processed (if insured through MassHealth or a commercial plan requiring PA). Cash-pay patients skip this step entirely.

Days 10 to 14: Pharmacy dispenses. Retail pharmacies may have Jatenzo in stock; if not, standard ordering takes 1 to 3 business days. Specialty pharmacies ship within 5 to 7 business days of PA approval.

Patients who already have confirmed low testosterone labs, use a cash-pay telehealth platform, and fill at a retail pharmacy with stock on hand can receive Jatenzo in as few as 5 days from initial sign-up.

Transferring a Jatenzo Prescription to Massachusetts

Patients relocating to Massachusetts can transfer their existing Jatenzo prescription from another state, subject to CIII transfer rules.

Under DEA regulations and Massachusetts Board of Pharmacy rules, Schedule III prescriptions can be transferred between pharmacies one time only (unless the pharmacies share a real-time electronic database). The receiving Massachusetts pharmacy must verify the original prescription, confirm remaining refills, and document the transfer per 247 CMR 8.00. Patients should contact their new Massachusetts pharmacy before running out to initiate the transfer process.

If the original prescription has no remaining refills, the patient will need a new prescription from a Massachusetts-licensed provider. Telehealth platforms can expedite this by reviewing medical records and prior labs from the transferring state's provider, often completing the visit and issuing a new Massachusetts prescription within 48 hours. The Massachusetts provider is not obligated to continue the same dose and may require updated labs if the most recent bloodwork is older than 6 months.